Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer.

ABSTRACT:

Background

Ovarian cancer is the eighth most common cancer among women and has a 5-year survival of only 30-50%. The survival is close to 90% for patients in stage I but only 20% for patients in stage IV. The presently available biomarkers have insufficient sensitivity and specificity for early detection and there is an urgent need to identify novel biomarkers.

Methods

We employed the Explore PEA technology for high-precision analysis of 1463 plasma proteins and conducted a discovery and replication study using two clinical cohorts of previously untreated patients with benign or malignant ovarian tumours (N = 111 and N = 37).

Results

The discovery analysis identified 32 proteins that had significantly higher levels in malignant cases as compared to benig

SUBMITTER: Gyllensten U 

PROVIDER: S-EPMC8997113 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature